Welcome Message
Dear Friends, WE ARE BACK! Stronger than ever!
The EASL Liver Cancer Summit has undoubtedly become the “MUST-ATTEND” event of the year for all those that are dealing with patients and research in liver cancer. Hepatologists, oncologists, interventional radiologists, surgeons, pathologists, scientist, nurses, patients will gather together in the beautiful city of Edinburgh to renew and reinforce our knowledge and efforts for the best management of our patients.
We are witnessing a true revolution in the development of therapeutic options in hepatocellular carcinoma and cholangiocarcinoma that more than ever require joint efforts to understand and manage the complexity of these tumours. To this end, basic, translational and clinical research are working together to answer unsolved medical needs
This is a unique opportunity to confront peers from different disciplines, to set the current standards in epidemiology, molecular pathogenesis and up-to-date knowledge of the management of liver tumours (including surgery, locoregional treatments, systemic therapies), to deep dive into the complexity of personalized medicine, and to foresee future challenges and opportunities in this rapidly changing and evolving field.
Basic science, clinical management, healthcare resources, patient advocacy, and controversies around hot topics: all this and much more is waiting for your contribution at EASL Liver Cancer Summit in Edinburgh on 22-24 January 2026.
The EASL Liver Cancer Summit 2026 Organisers
EASL Liver Cancer Summit 2026 Organising Committee
Irene Bargellini
Italy
Prof. Irene Bargellini is Associate Professor in the Department of Surgical Sciences of the University of Turin, Italy and Interventional Radiologists at the Interventional and Diagnostic Radiology Department of the University Hospital Città della Salute e della Scienza in Turin, Italy.
She was trained at the University Hospital of Pisa, where she worked as Interventional Radiologist from 2003 to 2022, later moving to Turin.
The main focus of her clinical and scientific work is on oncologic imaging and interventional oncology, with particular reference to liver imaging and liver tumors’ loco-regional and systemic therapies.
Prof. Bargellini is Member of the Executive Committee of Italian Society of Radiology (SIRM), fellow of the Cardiovascular and Interventional Radiology Society in Europe (CIRSE), and member of several other societies such as the Society of Interventional Oncology (SIO), the
European Society of Radiology (ESR), European Society for the Study of the Liver (EASL) and International Liver Cancer Association (ILCA).
She serves as reviewer for several national and international journals and is Member of the Editorial Board of European Radiology and Cardiovascular and Interventional Radiology journals. She has authored and co-authored over 120 articles in peer-review journals, is co-author of several book chapters, and has given over 350 invited lectures in national and international meetings.
Josep M. Llovet
Spain
Josep M Llovet, MD, PhD is Full Professor of Medicine and Director of the Liver Cancer Program at Icahn School of Medicine at Mount Sinai (New York), ICREA Research Prof at IDIBAPS-Hospital Clínic and Full Prof of Medicine-Hepatic Oncology at the Univ. of Barcelona.
I have published 359 manuscripts (h-index:157, citations:152,040), and have been awarded by Clarivate Analytics as a top 1% cited investigator in all years from 2014 to 2024. My research has been focused on clinical and translational studies in liver cancer for the last 30 years, with the following achievements: a) Leading author/ Principal investigator of RCT leading to standard of care therapies for hepatocellular carcinoma (HCC), such as systemic treatment (sorafenib), chemoembolization and the combination of lenvatinib plus pembrolizumab plus TACE, in intermediate HCC. In addition, I led proposals of molecular and immune classification of HCC (2008,2017, 2023) and established an imaging criteria for assessment of response to therapies (modified RECIST).
In terms of participation in scientific institutions, I have been Chair of EASL CPG of management of HCC; Editor in Chief of J HEP Reports; Founder, Secretary and President of the International Liver Cancer Association (ILCA); Founder and Director of the Mount Sinai Liver Cancer Program (2005-2023), the first program on liver cancer recognized by NCI in the USA;); Principal investigator of research funding with > 120 competitive grants, including coordinator of 2 European Union FP7 and Horizon Europe grants and 2 NIH-RO1
David Pinato
United Kingdom
Dr David J. Pinato is a Clinician Scientist and Consultant Medical Oncologist supported by the Wellcome Trust Strategic Fund (IPPRF scheme) working within the Department of Surgery and Cancer at Imperial College, London.
David leads a translational research program focusing on the early clinical implementation of novel experimental anticancer therapies to the clinic, with particular emphasis on anti-cancer immunotherapy. He has led the inception of a portfolio of first-in-class studies of immune checkpoint inhibitors in liver cancer, which has represented David’s focus of research since graduation with highest honours at the University of Piemonte Orientale “A. Avogadro” in Novara, Italy. David completed his research training being awarded a Masters of Research in Translational Medicine and a Ph.D. in Clinical and Experimental Medicine. Whilst at Imperial as a research fellow and Ph.D. student he developed considerable experience in translational oncology within the specific setting of early phase clinical trials. As part of his ongoing collaboration with the academic pathology unit at Imperial, David devoted his research interests to the immune-phenotyping of malignancy.
Matthias Pinter (EASL Governing Board representative)
Austria
Matthias Pinter works at the Medical University of Vienna, where he also received both his MD and PhD. He is board-certified for Internal Medicine, Gastroenterology & Hepatology, and Intensive Care Medicine.
He is leading the liver cancer program and research group at the Division of Gastroenterology & Hepatology, and is manager of the hepatobiliary tumor board at the Medical University of Vienna. Currently, he is also the head of the working group “Gastrointestinal Oncology” of the Austrian Society of Gastroenterology & Hepatology.
His main research interests include the systemic treatment of hepatocellular carcinoma, particularly the identification of prognostic markers and score as well as the development of strategies to improve the efficacy of systemic therapies. To broaden his knowledge and expertise in basic research and experimental oncology, he worked as a research fellow and postdoc at renowned institutions, including the University of Bern in Switzerland and the Massachusetts General Hospital/Harvard Medical School in the United States. He has published numerous original papers and review articles on liver cancer in prestigious peer-reviewed journals covering the categories Oncology, Gastroenterology & Hepatology, and Radiology.